Photobiomodulation Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy (NeuroLight 2)
Chemotherapy-induced Peripheral Neuropathy
About this trial
This is an interventional treatment trial for Chemotherapy-induced Peripheral Neuropathy focused on measuring Photobiomodulation therapy
Eligibility Criteria
Inclusion Criteria: Finished one of the following types of chemotherapy: paclitaxel, docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide and/or bortezomib. Diagnosed with CIPN Age 18 years or above Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis) Dutch-speaking Signed informed consent Exclusion Criteria: Taking stable doses of medication on prescription for peripheral neuropathy. Related medications are: gabapentin, pregabalin (Lyrica), nortriptyline, amitriptyline, duloxetine (Cymbalta), and venlafaxine. Severe or unstable cardio- respiratory or musculoskeletal disease Interruption of more than two consecutive laser treatments Dark brown or black skin pigmentation (described as skin type VI in the Fitzpatrick scale)
Sites / Locations
- Jessa HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Experimental: PBM1 group
Experimental: PBM2 group
The patients allocated to the first PBM-group will receive twelve PBM sessions of 6 J/cm² over six weeks (2x/week).
The patients allocated to the second PBM-group will receive twelve PBM sessions of 8 J/cm² over six weeks (2x/week).